Cantor Fitzgerald Remains a Buy on CytomX Therapeutics (CTMX)

Tip Ranks
2025.11.10 16:45
portai
I'm PortAI, I can summarize articles.

Cantor Fitzgerald analyst Olivia Brayer has maintained a Buy rating on CytomX Therapeutics (CTMX) with a price target of $6.00 as of November 6. Brayer, a 3-star analyst with a 39.06% success rate, also covers other healthcare stocks. Additionally, Piper Sandler's Edward Tenthoff issued a Buy rating for CytomX today, while TR | OpenAI reiterated a Hold rating on November 4.

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on CytomX Therapeutics on November 6 and set a price target of $6.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Brayer is a 3-star analyst with an average return of 3.5% and a 39.06% success rate. Brayer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, United Therapeutics, and CytomX Therapeutics.

In addition to Cantor Fitzgerald, CytomX Therapeutics also received a Buy from Piper Sandler’s Edward Tenthoff in a report issued today. However, on November 4, TR | OpenAI – 4o reiterated a Hold rating on CytomX Therapeutics (NASDAQ: CTMX).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer